



## Moolec Confirms US Harvest And Promising Yields For Plant-Grown Products GLASO™ And Piggy Sooy™ In October

**Luxembourg. September 05, 2024.** Moolec Science SA (NASDAQ: MLEC; “The Company”, “Moolec”), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024.

GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted acres of genetically modified safflower, mainly for commercial purposes. As a result of the harvest, Moolec is expecting to produce between 300 to 400 tons of safflower seeds that contain high levels of GLA. To allocate most of the upcoming GLASO™ production, Moolec has secured an offtake agreement with a major global CPG company, targeting the US market in 2025. Following a successful and rigorous audit from Moolec’s CPG customer production is set to begin in late 2024.

The Company is also developing a broader commercial strategy to reach larger markets and clients. Moolec’s GLASO™ product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market.

Piggy Sooy™ (porcine myoglobin in soybean seeds) field trials are being carried out in 3 different US locations: Ohio, Missouri and Iowa. Main purposes for the campaign are product development (sampling), seed increase and gathering of environmental and regulatory data to continue Moolec’s US-FDA approval pathway. The Team also projects a remarkable first open field performance for its bioengineered soybean Piggy Sooy™ after recent approval for cultivation from USDA-APHIS. This has set an unprecedented milestone in biotechnology last April, with Moolec becoming the first Molecular Farming company to obtain this kind of clearance for food crops growing animal proteins in US territory. Molecular Farming company to obtain this kind of clearance for food crops growing animal proteins in US territory.

Chief Technology Officer and Co-Founder Martín Salinas stated: *“Our commitment to scaling Moolec’s Molecular Farming Technology is demonstrated by our GLASO™ campaign and the field trials of Piggy Sooy™. These efforts not only reinforce our position as pioneers in the industry but also lay the foundation for sustainable solutions in agriculture and biotechnology.”* He then finished by remarking: *“One acre of Piggy Sooy™ could potentially produce pork meat proteins equivalent to 10 pigs, reducing water footprint, land usage and CO<sub>2</sub> emissions. This is a clear demonstration on how we promote environmental improvements throughout all our operations. Our aim is to heal the meat production system.”*



## About Moolec Science SA

Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for the food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins for the good of the planet. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. The Company's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. Moolec's product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean, pea, and safflower to produce oils and proteins. The Company has an industrial and commercial R&D capability to complement their Molecular Farming technology and secures a growing international patent portfolio (25+, both granted and pending) for its technology. Moolec is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit [moolecscience.com](http://moolecscience.com) and [ir.moolecscience.com](http://ir.moolecscience.com).

## Forward Looking Statements

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect,



actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

**Contacts:**

- Press & Media inquiries: [comms@moolecscience.com](mailto:comms@moolecscience.com)
- Investor Relations inquiries: [ir@moolecscience.com](mailto:ir@moolecscience.com) | [MoolecIR@icrinc.com](mailto:MoolecIR@icrinc.com)